（文章来源：北京商报） 北京商报讯9月30日晚间，科兴制药（688136）发布公告称，为深化科兴制药"创新+国际化"的战略布 局，加快海外业务发展，进一步提高公司综合竞争力及国际品牌形象，同时充分借助国际资本市场的资 源与机制优势，优化资本结构，拓宽多元融资渠道，公司拟发行H股股票并在香港联交所主板挂牌上 市。 ...

"A+H"上市持续升温。9月29日，广东潮宏基实业股份有限公司发布公告称，已向中国证监会报送了发 行境外上市股份（H股）并在香港联交所主板挂牌上市的备案申请材料，并于近日获中国证监会接收。 据《证券日报》记者不完全统计，9月份，已有20家A股上市公司宣布筹划赴港上市。从全年情况来 看，目前已有11家A股公司完成"A+H"上市，30余家公司正筹划赴港上市。 许多企业也将中国香港作为其全球化布局的"跳板"。例如，博瑞生物医药（苏州）股份有限公司的公告 显示，公司计划发行H股股票并在港交所主板上市，目的是加快国际化战略及海外业务布局，增强境外 融资能力。 广州若羽臣科技股份有限公司相关人士在接受《证券日报》记者采访时表示，赴港上市可拓宽全球视 野、整合全球资源，夯实品牌"出海"与供应链全球化竞争力，提升国际形象与品牌认知。 韩勇锋表示，中国香港作为全球资本"超级联系人"，是企业走向国际的天然平台。中东主权基金、北欧 养老金等国际长线资本，多通过港股配置中国资产。赴港上市既能提升品牌国际知名度，也能为跨境并 购、海外业务扩张等全球化战略提供资本运作支持。 这些大市值龙头企业通常处于快速扩张或战略转型期，大多需要资金支 ...

Performance Summary - In the first half of 2025, the company reported a revenue of 9.41 billion yuan, a year-on-year decline of 5.6%, and a net profit attributable to shareholders of 2.42 billion yuan, down 11.8% year-on-year [1] - In Q2 2025, the company achieved a revenue of 4.62 billion yuan, a significant year-on-year decline of 28.7%, with a net profit of 1.21 billion yuan, down 19.2% year-on-year [1] Revenue Breakdown - The decline in overall revenue was primarily due to a decrease in construction revenue, with a 0.99% decline when excluding construction income. However, toll revenue increased by 1.65%, with the average daily toll revenue on the Hu-Ning Expressway rising by 8.18% due to the impact of the Hu-Wu Expressway expansion [1] - Revenue from ancillary businesses decreased by 2.15%, despite an increase in oil sales volume, which was offset by a decline in sales price [1] - Revenue from the new energy sector fell by 3.7%, mainly due to reduced offshore wind power generation from the Yunshan Qingneng company's project in the Jiangsu region [1] - Real estate revenue plummeted by 84.9%, attributed to a decrease in delivery scale [1] Profitability and Costs - The company's gross margin for H1 2025 was 33.2%, an increase of 3.1 percentage points year-on-year, mainly due to a decrease in the proportion of zero-margin construction period revenue [2] - The company's expense ratio remained stable at 5.87%, with financial expenses decreasing by 0.11 percentage points to 4.7% due to lower interest rates [2] - Investment income fell to 700 million yuan, a decline of 33.2% year-on-year, primarily due to adjustments in the dividend cycle from Jiangsu Bank and the absence of asset disposal gains recorded in the previous year [2] Future Outlook - The company has adjusted its net profit forecasts for 2025-2027 to 5.04 billion yuan, 5.42 billion yuan, and 5.85 billion yuan, respectively, down from previous estimates [3] - The company continues to focus on cost reduction and efficiency improvements, optimizing existing road operations and utilizing diverse financing methods to lower financial costs [2]

格隆汇7月30日丨华恒生物(688639.SH)公布，公司为深入推进公司全球化发展战略，提升品牌影响力与 核心竞争力，巩固行业领先地位，充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元 融资渠道，全面提升公司治理水平和综合实力，正在筹划发行境外股份(H股)并在香港联合交易所有限 公司(以下简称"香港联交所")上市事宜(以下简称"本次H股上市")。公司正与相关中介机构就本次H股上 市的具体推进工作进行商讨，相关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发 生变化。 ...

华恒生物公告，公司正在筹划发行境外股份(H股)并在香港联合交易所有限公司上市。此举旨在深入推 进公司全球化发展战略，提升品牌影响力与核心竞争力，优化资本结构，拓宽多元融资渠道，全面提升 公司治理水平和综合实力。相关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发生 变化。 ...